Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 19/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17263106 | 0.85 | ACSS2 (0.76) | ACSS2 | |
| SCHEMBL17263139 | 0.85 | ACSS2 (0.82) | ACSS2 | |
| SCHEMBL18674922 | 0.84 | ACSS2 (0.80) | ACSS2 | |
| SCHEMBL18674919 | 0.82 | ACSS2 (0.71) | ACSS2 | |
| SCHEMBL17263104 | 0.79 | ACSS2 (0.76) | ACSS2 | |
| SCHEMBL18674920 | 0.79 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL18675042 | 0.78 | ACSS2 (1.00) | ACSS2SMN1; SMN2 | |
| SCHEMBL18674934 | 0.78 | ACSS2 (0.74) | ACSS2 | |
| SCHEMBL17263093 | 0.77 | ACSS2 (0.65) | ACSS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18674884 | 0.77 | ACSS2 (1.00) | ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015175845-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | ACSS2, GLS2, ACSL3 | ACSS2 1/4885KDM4E 2825/4885NPC1 2792/4885 |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | ACSS2, GLS2, ACSL3 | ACSS2 1/4885KDM4E 2825/4885NPC1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.